| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | mrkD |
| Uniprot No | P21648 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-321aa |
| 氨基酸序列 | WASCWQSNSAYEINMAMGRVVVSPDLPVGSVIATKTWTMPDNNTIYVTCDRNTTLKSDAKVVAAGLVQGANKVYSTAIPGIGLRFSRKGAISMIYPDSYTTTGSSFRLVGSTFTLDIIKTSTTTGSGTLASGPYTEYGPGFTILKTSLNADAITIVSPSCTILGGKNMNVDIGTIKRADLKGVGTWAGGTPFDIKLECSGGVSVSGYANINTSFSGTLATNTSANQGVLLNEKTGNSAAKGVGVQVIKDNTPLEFNKKHNIGTLQSQETRYITLPLHARFYQYAPTTSTGEVESHLVFNLTYD |
| 预测分子量 | 39.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于mrkD重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: *Expression and purification of recombinant MrkD adhesin from Klebsiella pneumoniae*
**作者**: Struve C, et al.
**摘要**: 该研究描述了大肠杆菌中肺炎克雷伯菌MrkD粘附素的重组表达与纯化过程，验证了其在宿主细胞粘附中的关键作用，并通过免疫印迹证实其抗原性。
2. **文献名称**: *Structural and functional analysis of the MrkD pilus adhesin in biofilm formation*
**作者**: Langstraat J, et al.
**摘要**: 文章解析了MrkD蛋白在生物膜形成中的结构功能，通过重组蛋白实验证明其与宿主细胞表面受体互作，并揭示了特定结构域对致病性的影响。
3. **文献名称**: *Immunogenicity of recombinant MrkD as a vaccine candidate against Klebsiella infections*
**作者**: Murphy CN, et al.
**摘要**: 研究评估了重组MrkD蛋白作为疫苗的潜力，动物实验显示其能诱导特异性抗体并增强对肺炎克雷伯菌感染的保护作用。
(注：以上文献为示例，实际引用需根据具体数据库检索结果调整。)
**Background of MrkD Recombinant Protein**
MrkD is a key adhesin component of the type III fimbriae produced by *Klebsiella pneumoniae*, a Gram-negative bacterial pathogen associated with hospital-acquired infections, including pneumonia, urinary tract infections, and sepsis. These fimbriae mediate bacterial adhesion to host surfaces, particularly endothelial and epithelial cells, as well as abiotic materials like catheters, facilitating biofilm formation and colonization. MrkD, located at the tip of the fimbrial structure, plays a critical role in recognizing and binding to host extracellular matrix components, such as collagen, enhancing bacterial persistence and virulence.
Recombinant MrkD protein is generated through genetic engineering, typically by cloning the *mrkD* gene into expression vectors (e.g., *E. coli*) to produce purified protein for functional and immunological studies. Its production enables researchers to study host-pathogen interactions, immune responses, and mechanisms of biofilm formation without handling live pathogens. Additionally, recombinant MrkD serves as a potential target for therapeutic interventions. Studies explore its utility in vaccine development, as antibodies against MrkD can block bacterial adhesion and reduce infection severity. It also aids in diagnostic tool design to detect *K. pneumoniae* infections.
Research on MrkD is particularly relevant amid rising antibiotic resistance in *K. pneumoniae* strains. Understanding its structure-function relationship and role in virulence may lead to novel anti-adhesion therapies or preventive strategies, addressing unmet needs in combating multidrug-resistant infections. Overall, MrkD recombinant protein is a valuable tool in both basic research and translational applications against *Klebsiella*-related diseases.
×
